Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.

Luca QuartuccioArianna SonagliaDavide PecoriMaddalena PeghinMartina FabrisCarlo TasciniSalvatore De Vita

Published in: Journal of medical virology (2020)

Repeated measurement of the serum level of IL-6 early after tocilizumab may distinguish nonsurvivors from survivors and support the choice of deeper targeting IL-6 in COVID-19 pneumonia.

Keyphrases

coronavirus disease
sars cov
rheumatoid arthritis
cancer therapy
rheumatoid arthritis patients
drug delivery
respiratory failure
disease activity